免疫查核點抑制劑市場：依藥物類別、癌症類型、通路和地區分類

Immune Checkpoint Inhibitors Market, By Drug Class, By Cancer Type, By Distribution Channel, By Geography

出版日期: 2026年02月19日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，免疫查核點抑制劑市場規模將達23.696億美元，2033年將達到56.156億美元。預計從2026年到2033年，其複合年成長率將達到13.2%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	23.696億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	13.20%	2033年市場規模預測：	56.156億美元

免疫查核點抑制劑是免疫腫瘤療法的一部分，利用患者自身的免疫系統攻擊癌細胞。免疫腫瘤療法採用新型免疫療法，例如免疫查核點抑制劑，來活化患者的免疫系統。這些療法針對的是人體的免疫系統而非腫瘤本身，使免疫系統能夠識別並攻擊癌細胞。免疫查核點抑制劑是一種免疫治療產品，它能夠抑制阻止免疫系統攻擊癌細胞的蛋白質。這些藥物抑制特定的查核點蛋白，例如 CTLA-4、PD-1 和 PD-L1。製造商正在研發免疫查核點抑制劑，用於聯合治療。免疫查核點抑制劑對多種癌症有效，包括非小細胞肺癌、淋巴瘤、皮膚癌和乳癌。根據其作用機制，這些治療方法進一步分為程序性死亡受體-1 (PD-1) 抑制劑、程序性死亡配體-1 (PD-L1) 抑制劑和細胞毒性T淋巴細胞抗原4 (CTLA-4) 抑制劑等亞型。市售的免疫查核點抑制劑包括Ipilimumab、Nivolumab、Rituximab、Blinatumomab、普羅萊Proleukin、Gardasil和凱姆瑞。

市場動態

癌症發生率的上升預計將推動全球免疫查核點抑制劑市場的發展。例如，根據美國癌症協會預測，2022年美國將新增1918,030例癌症病例，並有609,360例癌症相關死亡病例，其中肺癌是癌症死亡的主要原因，每天約有350人死於肺癌。 2022年，中國和美國預計分別新增約482萬例癌症病例和237萬例癌症病例，以及321萬例和64萬例癌症相關死亡病例。（2022年新增癌症病例和死亡病例估計：2022年，美國預計新增癌症病例190萬例，癌症相關死亡病例609360例。）

本次調查的主要特點。

本報告對全球免疫查核點抑制劑市場進行了詳細分析，以 2021 年為基準年，給出了預測期（2022-2030 年）的市場規模和複合年成長率。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球免疫查核點抑制劑市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過對全球免疫查核點抑制劑市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
公司簡介
- Bristol-Myers Squibb Company
- Merck &Co., Inc.
- F. Hoffmann-La Roche AG
- AstraZeneca Plc
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.

第9章

參考
調查方法

簡介目錄

Product Code: CMI2560

Immune Checkpoint Inhibitors Market is estimated to be valued at USD 2,369.6 Mn in 2026 and is expected to reach USD 5,615.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,369.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.20%	2033 Value Projection:	USD 5,615.6 Mn

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)

Key features of the study

This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immune checkpoint inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market

Market Segmentation

By Drug Class
- Programmed Death Receptor-1 (PD-1) Inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Cemiplimab (Libtayo)
- Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
- Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer
- Melanoma
- Merkel Cell Carcinoma
- Blood Cancer
- Lymphoma
- Bladder Cancer
- Urothelial Carcinoma
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- AstraZeneca Plc.
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Epidemiology
Collaborations & Partnerships
Major FDA Approvals & Product Launch Scenario
Pipeline Analysis
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Programmed Death Receptor-1 (PD-1) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Pembrolizumab (Keytruda)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Nivolumab (Opdivo)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Cemiplimab (Libtayo)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Atezolizumab (Tecentriq)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Avelumab (Bavencio)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Durvalumab (Imfinzi)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
CTL-4 Checkpoint Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Ipilimumab (Yervoy)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Lymphocyte-Activation Gene 3 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global Immune Checkpoint Inhibitors Market, By Cancer Type, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Head & Neck Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Blood Cancer (Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Bladder Cancer (Urothelial Carcinoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Renal/Kidney Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global Immune Checkpoint Inhibitors Market, By Region, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- F. Hoffmann-La Roche AG
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AstraZeneca Plc
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis International AG
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- ImmunOs Therapeutics AG
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Immutep Ltd.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- NewLink Genetics Corporation
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Ono Pharmaceutical Co., Ltd.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies